Live Breaking News & Updates on Stephenj Farr

Stay updated with breaking news from Stephenj farr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zogenix : Amendment to Annual Report (Form 10-K/A)

10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM
. | March 7, 2022 ....

United States , United Kingdom , Redwood City , Research Triangle Park , North Carolina , San Diego , Syracuse University , District Of Columbia , San Francisco , University Of Southern California , New Jersey , New York , University Of Arizona , Rutgers University , Stanford University , Dana Farber Cancer Institute , South Ayrshire , University Of California San Francisco , Bradleym Galer , Reneep Tannenbaum , Peter Kolchinsky , Ruperth Johnson Jr , Eli Lilly , Bristol Meyers Squibb , Paul Hastings , Los Angeles ,

Zogenix, Inc: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced ....

United States , Porter Novelli , Trish Mccall , Tevard Biosciences , Stephenj Farr , Brian Ritchie , Us Securities Exchange Commission , Nippon Shinyaku Co Ltd , Lifesci Advisors , Zogenix Access Program , Drug Application To Japan Ministry Of Health , Drug Administration , Zogenix Inc , American Epilepsy Society Annual Meeting , Exchange Commission , Japanese Ministry Of Health , European Medicines Agency , Zinc Merger Sub Inc , Priority Review , Supplemental New Drug Application , Lennox Gastaut Syndrome , New Drug Application , Access Program , Japanese Ministry , American Epilepsy Society Annual , Fourth Quarter ,

UCB to acquire Zogenix

/PRNewswire/ Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered. ....

United States , Bruxelles Capitale , Dravetc Dravet , Charl Van Zyl , Tevard Biosciences , Stephenj Farr , Zogenix Inc , Zinc Merger Sub Inc , Committee For Medicinal Products Human Use , National Institute Of Neurological Disorders , Neurology Head Of Europe International , Statement Of Zogenix Inc , Drug Administration , Latham Watkins , Covington Burling , Exchange Commission , Zogenix Press , European Medicines Agency , New Drug Application , Priority Review , Executive Vice President , International Markets , Chief Executive Officer , Zinc Merger Sub , Capital Markets Call , Prescribing Information ,

UCB to acquire Zogenix (2)

- Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to,. ....

United States , Bruxelles Capitale , Dravetc Dravet , Charl Van Zyl , Tevard Biosciences , Stephenj Farr , Zogenix Inc , Zinc Merger Sub Inc , Committee For Medicinal Products Human Use , National Institute Of Neurological Disorders , Neurology Head Of Europe International , Statement Of Zogenix Inc , Drug Administration , Latham Watkins , Covington Burling , Exchange Commission , Zogenix Press , European Medicines Agency , New Drug Application , Priority Review , Executive Vice President , International Markets , Chief Executive Officer , Zinc Merger Sub , Capital Markets Call , Prescribing Information ,

UCB to acquire Zogenix

/PRNewswire/ Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered. ....

United States , Bruxelles Capitale , Dravetc Dravet , Charl Van Zyl , Tevard Biosciences , Stephenj Farr , Zogenix Inc , Zinc Merger Sub Inc , Committee For Medicinal Products Human Use , National Institute Of Neurological Disorders , Neurology Head Of Europe International , Statement Of Zogenix Inc , Drug Administration , Latham Watkins , Covington Burling , Exchange Commission , Zogenix Press , European Medicines Agency , New Drug Application , Priority Review , Executive Vice President , International Markets , Chief Executive Officer , Zinc Merger Sub , Capital Markets Call , Prescribing Information ,